# The Role of Ultrasound Pleural Irregularities in the Identification of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies

**Authors:** Linda Carli, Simone Barsotti, Chiara Romei, Andrea Delle Sedie, Federico Fattorini, Michele Diomedi, Elisa Cioffi, Elenia Laurino, Chiara Cardelli, Gaetano La Rocca, Marta Mosca

PMC · DOI: 10.3390/jpm16030162 · 2026-03-14

## TL;DR

This study explores how ultrasound can help detect lung disease in patients with muscle inflammation by analyzing pleural irregularities.

## Contribution

The study demonstrates that lung ultrasound can be a useful diagnostic tool for interstitial lung disease in inflammatory myopathy patients.

## Key findings

- Pleural irregularities were more frequent in patients with myositis-specific autoantibodies and high-grade dyspnea.
- Pleural irregularities correlated negatively with pulmonary function tests and positively with HRCT scores.
- Lung ultrasound could reduce the need for high-resolution CT scans in these patients.

## Abstract

Background: Interstitial lung disease (ILD) is the most frequent extra-muscular manifestation in patients with idiopathic inflammatory myopathies (IIMs). Although high-resolution chest tomography (HRCT) represents the gold standard for the evaluation of ILD, lung ultrasound (LUS) might be a useful tool for its assessment. The aim of our study was to evaluate the number and distribution of pleural irregularities (PIs) identified by lung US in a cohort of patients with IIMs and to find possible correlations with clinical, serological and HRCT data to verify the potential usefulness of lung US for the study of ILD in patients with IIM. Patients and methods: Fifty-three patients with IIM according to EULAR/ACR classification criteria were enrolled. All patients underwent a clinical evaluation with measurement of disease activity and myositis-specific autoantibodies, pulmonary function tests, HRCT evaluated with the Warrick score, and lung US for the measurement of PIs. Results: The number of PIs was higher in patients with myositis-specific autoantibodies, particularly those with anti-synthetase autoantibodies (p < 0.001) and in patients with high-grade dyspnea (p < 0.03). A negative correlation was identified between PIs and pulmonary function tests, particularly TLC (r = −0.74; p < 0.001) and DLCO (r = −0.56; p < 0.001). Interestingly, PI score was higher in patients with ILD identified with HRCT (p = 0.015) and a positive correlation between PIs and Warrick score (r = 0.542; p < 0.001) was also found. Conclusions: The study of PIs with lung US represents a promising diagnostic tool for the bedside evaluation of patients with IIMs. This can possibly allow for a reduction in unnecessary HRCTs, reducing the exposition of patients to ionizing radiations, optimizing resources and reducing the costs of patients’ management.

## Linked entities

- **Diseases:** interstitial lung disease (MONDO:0015925), idiopathic inflammatory myopathies (MONDO:0020122)

## Full-text entities

- **Genes:** IFIH1 (interferon induced with helicase C domain 1) [NCBI Gene 64135] {aka AGS7, Hlcd, IDDM19, IMD95, MDA-5, MDA5}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, CD200 (CD200 molecule) [NCBI Gene 4345] {aka MOX1, MOX2, MRC, OX-2}, TRIM33 (tripartite motif containing 33) [NCBI Gene 51592] {aka DDH4, ECTO, PTC7, RFG7, TF1G, TIF1G}, MORC3 (MORC family CW-type zinc finger 3) [NCBI Gene 23515] {aka NXP2, ZCW5, ZCWCC3}
- **Diseases:** ASyS (MESH:D020159), muscular hyposthenia (MESH:D009135), UIP (MESH:D054990), Idiopathic Inflammatory Myopathies (MESH:D009220), ILD (MESH:D017563), pulmonary infections (MESH:D012141), injury to (MESH:D014947), autoimmune diseases (MESH:D001327), SLE (MESH:D008180), air trapping (MESH:C536657), Connective tissue disease (MESH:D003240), BLs (MESH:D006509), Infections (MESH:D007239), cysts (MESH:D003560), IBM (MESH:D018979), PIs (MESH:D010995), chronic (MESH:D002908), viral or infectious pneumonitis (MESH:D018792), Cardiac disease (MESH:D006331), overweight (MESH:D050177), Pulmonary involvement (MESH:C566343), PAH (MESH:D000081029), bacterial pneumonia (MESH:D018410), pulmonary malignancy (MESH:D009369), Heart failure (MESH:D006333), SS (MESH:D012859), respiratory muscle weakness (MESH:D018908), myocarditis (MESH:D009205), IIM (MESH:D056728), asthma (MESH:D001249), pneumothorax (MESH:D011030), Spondyloarthritides (MESH:D013167), pleural effusion (MESH:D010996), influenza (MESH:D007251), chronic cough (MESH:D003371), OP (MESH:D000092124), chronic obstructive pulmonary disease (MESH:D029424), respiratory dysfunction (MESH:D012131), DAD (MESH:D000070625), valvular disease (MESH:D006349), dyspnea (MESH:D004417), LUS (MESH:D008171), DM (MESH:D003882), PM (MESH:D017285), inflammatory lung involvement (MESH:D016726), SARS-CoV-2 (MESH:D000086382), CMV (MESH:D003586), arrhythmias (MESH:D001145), atelectasis (MESH:D001261), RA (MESH:D001172), SSc (MESH:D012595), inflammatory (MESH:D007249)
- **Chemicals:** mycophenolate mofetil (MESH:D009173), GC (MESH:C057580), HRCT (-), cyclophosphamide (MESH:D003520), carbon monoxide (MESH:D002248), rituximab (MESH:D000069283), natriuretic peptides (MESH:D045265)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027697/full.md

---
Source: https://tomesphere.com/paper/PMC13027697